Montgomery SA / Thompson C. Management / John Wiley & Sons Ltd. / GE / Delphi / NHS Limited / MEDTAP International Inc. / Old Age Depression Interest Group / Jonsson and Bebbington / /
Continent
Europe / /
Country
Germany / France / United States / Canada / Australia / United Kingdom / /
Currency
GBP / USD / FRF / /
Facility
Hospital Medical School / University of Kent / /
IndustryTerm
healthcare organizations / healthcare budgets / treatment of depression / treatment for depression / pharmaceutical industry / comparator product / health services / health care technologies / reimbursement systems / healthcare / decisions on whether new products / The pharmaceutical industry / pharmaceutical prices / pharmaceuticals / placebo / treatment of recurrent depressive disorders / target patient / higherprice pharmaceutical innovation / insurance costs / sickness insurance / pharmaceutical treatments / health care finance / health care systems / insurance system / social care services / healthcare providers / pharmaceutical pricing / social insurance system / price products / /
US Public Health Service / Health Policy Unit / QALY league / National Centre for Health Program Evaluation / University of Kent at Canterbury / NS NS / St Mary’s Hospital Medical School / Department of Health / NHS / /
Person
Stewart A. Antidepressant / Beck JR. / Nutt D. Selective / Sheldon T. Problems / Morris J. Br / Martin Knapp / Stewart A. Choosing / Mason J. Selective / /
Position
psychiatrist / General / author / step forward / model / Professor / Marshall / /
The Journal of Mental Health Policy and Economics J. Mental Health Policy Econ. 1, 41–Cost-Effectiveness of SSRIs: A European Perspective Alan Stewart*, M.A. (Cambridge), MSc. (York)